Intratumoral Microbiome–related MRI Model for Predicting                     Breast Cancer Shrinkage Pattern Following Neoadjuvant Therapy

An intratumoral microbiome–related MRI model accurately predicted tumor shrinkage pattern after neoadjuvant therapy, demonstrating potential to assist in planning breast-conserving surgery.

Topics

No keywords indexed for this article. Browse by subject →

References

34

[1]

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel et al.

CA: A Cancer Journal for Clinicians 10.3322/caac.21660

[2]

10.1200/jco.20.03399

[3]

10.1186/s13058-024-01781-1

[4]

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Patricia Cortazar, Lijun Zhang, Michael Untch et al.

The Lancet 10.1016/s0140-6736(13)62422-8

[5]

10.6004/jnccn.2022.0030

[6]

10.1148/rycan.230033

[7]

10.1148/radiol.12110748

[8]

10.1158/1078-0432.ccr-18-3190

[9]

10.1016/j.ebiom.2021.103460

[10]

10.1001/jamanetworkopen.2020.28086

[11]

10.1016/j.acra.2023.10.010

[12]

10.3389/fbioe.2021.662749

[13]

10.1016/j.tranon.2020.100831

[14]

10.1148/radiol.2019182718

[15]

Zhu T Int J Surg (2023) 10.1097/js9.0000000000000621

[16]

10.1016/j.eclinm.2023.101899

[17]

10.1158/1078-0432.ccr-20-2156

[18]

10.1109/rbme.2021.3136343

[19]

Medical image analysis using deep learning algorithms

Mengfang Li, Yuanyuan Jiang, Yanzhou Zhang et al.

Frontiers in Public Health 10.3389/fpubh.2023.1273253

[20]

10.1177/20552076221074122

[21]

10.1016/j.compbiomed.2024.108132

[22]

10.1016/j.ejrad.2023.111159

[23]

10.1186/s12967-025-06369-7

[24]

10.1186/s12929-025-01117-x

[25]

10.1002/advs.202413702

[26]

10.1016/j.acra.2023.02.024

[27]

10.1016/j.compbiomed.2022.106073

[28]

10.1186/s12885-025-13678-z

[29]

10.1186/s13058-025-02009-6

[30]

10.1016/j.ejrad.2024.111312

[31]

10.1148/radiol.2018181352

[32]

10.1007/s11547-024-01796-w

[33]

10.1038/s41467-024-53450-8

[34]

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2 -Positive RAS Wild-Type Colorectal Cancer

Sandra J. Casak, M. Naomi Horiba, Mengdie Yuan et al.

Clinical Cancer Research 10.1158/1078-0432.ccr-23-1041

Metrics

5

Citations

34

References

Details

Published: Aug 01, 2025
Vol/Issue: 316(2)

Authors

X

Xinyang Song

Department of Radiology, First Affiliated Hospital of Jinan University, Guangzhou, China

Y

YiLin Chen

Department of Breast Cancer, Cancer Center, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106 Zhongshan 2nd Rd, Yuexiu District, Guangzhou 510080, China

H

Han Qiu

Galactophore Department, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, China

T

Tianhan Zhou

Department of General Surgery, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China

S

Siqi Wang

Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Mass

Y

Yang Zhou

Department of Pathology, Affiliated Changzhou Second People’s Hospital of Nanjing Medical University, Changzhou, China

W

Wei Li

Department of Breast Cancer, First People’s Hospital of Foshan, Foshan, China

Y

Ying Lin

Breast Disease Center, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Q

Qian Wang

Department of Radiology, Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huai’an, China

W

Wenchao Gu

Department of Artificial Intelligence Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan

T

Teng Zhu

Department of Breast Cancer, Cancer Center, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106 Zhongshan 2nd Rd, Yuexiu District, Guangzhou 510080, China

K

Kun Wang

Department of Breast Cancer, Cancer Center, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106 Zhongshan 2nd Rd, Yuexiu District, Guangzhou 510080, China

Funding

National Natural Science Foundation of China Award: 82171898

Guangdong Basic and Applied Basic Research Foundation Award: 2022A1515012277

Deng Feng Project of High-Level Hospital Construction Award: DFJHBF202109

Cite This Article

Xinyang Song, YiLin Chen, Han Qiu, et al. (2025). Intratumoral Microbiome–related MRI Model for Predicting Breast Cancer Shrinkage Pattern Following Neoadjuvant Therapy. Radiology, 316(2). https://doi.org/10.1148/radiol.243545

Intratumoral Microbiome–related MRI Model for Predicting Breast Cancer Shrinkage Pattern Following Neoadjuvant Therapy

You May Also Like